NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemotherapy (NAC) in stage II-IV rectal cancer.

George, TJ; Yothers, G; Lee, JJ; Jacobs, SA; Deutsch, M; Allegra, CJ

JOURNAL OF CLINICAL ONCOLOGY, 2018; 36 (15):